US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
RSS Feeds

Biotechnology Industry Research & Market Reports

5  6  7  8    10    12  13  14  
China Recombinant Protein Drug Industry Report, 2014-2017
11/19/2014 | published by: Research in China
... protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014. The start ...  |  read more...
USD 2,500
Conference Documentation: Advances in Cell Based Assays
11/11/2014 | published by: SMI Publishing, Ltd
... and strategies to accelerate go/no-go decision making in early and clinical development. Key academic, government and industry figures cover topics encompassing: Case studies in idiopathic pulmonary fibrosis (IPF) and molecular characterisation of solid tumors Interactive ...  |  read more...
USD 788.78
Anti-CD22 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD22 Antibody. This report provides information on the therapeutic development based on the Anti-CD22 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD25 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD25 Antibody. This report provides information on the therapeutic development based on the Anti-CD25 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Anti-CD274 (PD-L1) Antibody. This report provides information on the therapeutic development based on the Anti-CD274 (PD-L1) Antibody dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Anti-CD279 (PD-1) Antibody. This report provides information on the therapeutic development based on the Anti-CD279 (PD-1) Antibody dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
Anti-CD3 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD3 Antibody. This report provides information on the therapeutic development based on the Anti-CD3 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD38 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD38 Antibody. This report provides information on the therapeutic development based on the Anti-CD38 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD4 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD4 Antibody. This report provides information on the therapeutic development based on the Anti-CD4 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD40 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD40 Antibody. This report provides information on the therapeutic development based on the Anti-CD40 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD52 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD52 Antibody. This report provides information on the therapeutic development based on the Anti-CD52 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD6 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD6 Antibody. This report provides information on the therapeutic development based on the Anti-CD6 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD80 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD80 Antibody. This report provides information on the therapeutic development based on the Anti-CD80 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CD95 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CD95 Antibody. This report provides information on the therapeutic development based on the Anti-CD95 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-CS1 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... for all the pipeline drugs that fall under Anti-CS1 Antibody. This report provides information on the therapeutic development based on the Anti-CS1 Antibody dealing with mechanism of action, comparative analysis at various stages covering Filed, ...  |  read more...
USD 1,250
Anti-Dickkopf-1 (Dkk-1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Anti-Dickkopf-1 (Dkk-1) Antibody. This report provides information on the therapeutic development based on the Anti-Dickkopf-1 (Dkk-1) Antibody dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
2014-2018 Global CA Tumor Markers Testing Market: Emerging Opportunities, Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Landscape--US, Europe (France, Germany, Italy, Spain, UK), Japan
11/4/2014 | published by: VPGMarketResearch.com
... the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting ...  |  read more...
USD 5,450
2014-2018 European Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK
11/12/2014 | published by: VPGMarketResearch.com
... major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players ...  |  read more...
USD 19,700
2014-2018 World Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Japan, Spain, UK, US
11/12/2014 | published by: VPGMarketResearch.com
... opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; ...  |  read more...
USD 34,500
Interferon-Alpha/Beta Receptor Binders -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... the understanding for all the pipeline drugs that fall under Interferon-Alpha/Beta Receptor Binders. This report provides information on the therapeutic development based on the Interferon-Alpha/Beta Receptor Binders dealing with mechanism of action, comparative analysis at ...  |  read more...
USD 1,250
Fibroblast Growth Factor Receptor (FGFR) Agonists -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... of the report is to establish the understanding for all the pipeline drugs that fall under Fibroblast Growth Factor Receptor (FGFR) Agonists. This report provides information on the therapeutic development based on the Fibroblast Growth ...  |  read more...
USD 1,250
Fibroblast Growth Factor Receptor (FGFR) Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... of the report is to establish the understanding for all the pipeline drugs that fall under Fibroblast Growth Factor Receptor (FGFR) Inhibitors. This report provides information on the therapeutic development based on the Fibroblast Growth ...  |  read more...
USD 1,250
Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists. This report provides information on the therapeutic development based on ...  |  read more...
USD 1,250
Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fibroblast Growth Factor Receptor 1 (FGFR1) Inhibitors. This report provides information on the therapeutic development based on ...  |  read more...
USD 1,250
G-Protein Coupled Receptor (GPCR) Agonists -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... report is to establish the understanding for all the pipeline drugs that fall under G-Protein Coupled Receptor (GPCR) Agonists. This report provides information on the therapeutic development based on the G-Protein Coupled Receptor (GPCR) Agonists ...  |  read more...
USD 1,250
5  6  7  8    10    12  13  14